Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × palbociclib × CNS × Clear all

Phase

Phase 2 7 Phase 1 2 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 19 Other solid neoplasm 4 Thoracic 3 Gynecologic 3 Head & Neck 2 Gastrointestinal 2 Dermatologic 2 Tumor-Agnostic 1 Sarcoma 1 Other hematologic neoplasm 1 Genitourinary 1 CNS 1

Conditions

Interventions

Temozolomide 94 Radiotherapy 43 Bevacizumab 29 Carboplatin 22 Irinotecan 18 Radiosurgery 16 pembrolizumab 15 Radiation 14 Nivolumab 14 Magnetic Resonance Spectroscopy 9 Cyclophosphamide 9 Trastuzumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Pemetrexed 7 Paclitaxel 7 Interleukin-2 7 Filgrastim 7 Erlotinib Hydrochloride 7 Carmustine 7 fludarabine 6 Specimen Handling 6 Ipilimumab 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 Everolimus 6 Capecitabine 6 aldesleukin 5 Vorinostat 5 Radiotherapy, Conformal 5 Melphalan 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03158389 2023-09-28

N²M²

University Hospital Heidelberg

Phase 1/2 Completed

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡